Clinical trial · Observational
Transcriptional Responses as an Indicator of Individualised Responses to Radiation Effects (RTGene 2)
Multi-panel Coding and Non-coding Transcriptional Responses as an Indicator of Individualised Responses to Radiation Effects in Radiation Therapy Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Peripheral blood samples will be taken with informed consent from radiotherapy patients before and during treatment fractions for sarcoma, breast, lung, gut, genitourinary and head \& neck tumours at The Royal Marsden. Candidate genes identified by PHE, Columbia and/or in the literature as being specific to radiation responses will be assessed, together with genes relevant to systemic inflammatory and immune responses, to identify transcriptional responses for a range of doses and exposures on an inter-individual basis. Data will be analysed using existing and new statistical tools focused on count data modelling. The intended outcome is identification of a radiation specific panel of genes to inform individual radiation responses and if the results are favourable, a large scale follow up to this project is expected.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood donation during radiotherapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Blood donation during radiotherapy
- description
- Participants will be asked to donate a blood sample at 5 time points during and after radiotherapy
- interventionNames
- Procedure: Blood donation during radiotherapy
Primary outcomes (1)
- measure
- Validation of new transcriptional techniques
- timeFrame
- 24 months after all participants have finished radiotherapy and donated blood samples
- description
- Using nCounter platform to validate biomarkers of individual radiation exposure, in vivo
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years * Requirement for external beam radiotherapy (large-field RT, over at least 2 weeks) for sarcoma, breast, lung, gastrointestinal, head \& neck or genitourinary tumours * Written informed consent Exclusion Criteria: * Previous radiotherapy * Concurrent chemotherapy/biological therapy or chemotherapy/biological therapy preceding radiotherapy by less than 4 weeks * Concurrent hormone therapy or hormone therapy preceding radiotherapy by less than 4 weeks
References
Publications (0)
Data not yet available